InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Subsidiary Active Intelligence to Showcase Wellness Products at ECRM Conference
May 15, 2026
Nutriband (NASDAQ: NTRB) announced that its wholly owned subsidiary, Active Intelligence, will participate in the June 2026 ECRM conference, where it plans to showcase its expanding portfolio of wellness, recovery and performance-focused consumer products to buyers from major retail, pharmacy and healthcare organizations. The company will feature its existing AI Tape line and introduce new products including AI Performance Tape, AI Energy Patches and […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Highlights AVERSA Technology on Jack Neel Podcast
April 22, 2026
Nutriband (NASDAQ: NTRB) announced that CEO and Co-Founder Gareth Sheridan appeared on the Jack Neel Podcast to discuss the opioid crisis and the company’s AVERSA(TM) abuse-deterrent transdermal technology. The episode outlines how AVERSA(TM) is designed to reduce misuse, diversion, and accidental exposure of high-risk drugs such as fentanyl, while maintaining patient access, and is supported by a broad […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Selects Global Brand Name Candidate for AVERSA(TM) Fentanyl Patch
March 31, 2026
Nutriband (NASDAQ: NTRB) announced it has selected a proposed worldwide brand name for its abuse-deterrent fentanyl transdermal system, with plans to submit the name and product labeling to the FDA and international regulators as well as file for trademark protection. The company said the product, developed using its AVERSA(TM) technology, could become the first abuse-deterrent […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Costa Rica Approval for Kinesiology Tape Line
March 18, 2026
Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health has approved its line of kinesiology tapes for import and sale, with exclusive distribution partner Innomedica CCB overseeing and financing the regulatory process. The company plans to ramp up marketing efforts in partnership with Innomedica, targeting both its kinesiology tape products and mosquito repellent patch line following the […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Signs Exclusive Costa Rica Distribution Deal for AVERSA Fentanyl and Sports Tape Products
February 17, 2026
Nutriband (NASDAQ: NTRB) announced it has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA Fentanyl, upon approval, and all sports tape products manufactured at its Pocono Pharmaceutical/Active Intell subsidiary. Under the agreement, Innomedica will oversee and finance regulatory approvals as the products advance toward launch. Nutriband’s AVERSA abuse-deterrent transdermal technology is designed to incorporate aversive agents into patches to deter […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting
January 30, 2026
Nutriband (NASDAQ: NTRB) (NASDAQ: NTRBW) provided shareholders with an update following its 2026 Annual Shareholders Meeting held Jan. 24, 2026, in Orlando, Florida, highlighting the appointment of two new directors, Alessandro Puddu and Viorica Carlig, and outlining key progress in the development of AVERSA(TM) FENTANYL. During 2025, the company strengthened its exclusive partnership with Kindeva, completed commercial manufacturing scale-up, expanded global patent […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting 2025 Milestones and 2026 Outlook
December 31, 2025
Nutriband (NASDAQ: NTRB) announced that Chief Executive Officer Gareth Sheridan has published a letter to shareholders outlining key achievements during 2025 and providing perspective on the Company’s priorities and outlook for 2026. The update highlighted Nutriband’s continued focus on shareholder value, including disciplined capital management, a 25% preferred stock dividend issued in 2025, and progress […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sells 90% Stake in Pocono Pharmaceutical for $5 Million
December 29, 2025
Nutriband (NASDAQ: NTRB) announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million, while retaining a 10% ownership interest following the transaction. The company said proceeds from the sale will be used to support continued development of AVERSA Fentanyl, a transdermal opioid […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration
December 19, 2025
Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced computing, and cybersecurity technologies that may support Nutriband’s research and long-term product development initiatives. The company said the discussions will focus on areas such as secure AI and analytics platforms for regulated pharmaceutical data, […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Responds to Fentanyl WMD Executive Order, Highlights AVERSA(TM) FENTANYL Development
December 18, 2025
Nutriband (NASDAQ: NTRB) said the Trump Administration Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction should not be conflated with “FDA”-approved prescription fentanyl therapies such as transdermal fentanyl patches, which it said are produced under rigorous regulatory oversight and remain medically necessary for certain severe chronic pain patients. The White House+1 The company noted […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Chairman Presentation at NobleCon21
November 24, 2025
Nutriband (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets’ annual emerging growth equity conference, on Dec. 3 at 9:30 a.m. Eastern at Florida Atlantic University’s Executive Education Complex in Boca Raton, Florida. Investors and guests may attend at a discounted rate using code NTRBNOBLECON, and a high-definition […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission
October 28, 2025
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received final meeting minutes from its Sept. 18, 2025, virtual meeting with the U.S. Food and Drug Administration (FDA) regarding its lead product, AVERSA(TM) FENTANYL, an abuse-deterrent fentanyl transdermal system. The meeting with the Division of Anesthesiology, Addiction Medicine, and Pain […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl
October 27, 2025
Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as CEO, effective immediately, following a temporary period during which Co-Founder and Chairman Serguei Melnik served in the position. Sheridan will lead the company through its final 2025 development framework toward an expected 2026 NDA filing for AVERSA Fentanyl, the company’s […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Featured in Channelchek Report Highlighting AVERSA Fentanyl Progress
October 24, 2025
Nutriband (NASDAQ: NTRB), a pharmaceutical company developing transdermal drug delivery technologies, was featured in a Channelchek report by Noble Capital Markets summarizing its presentation at Noble’s Virtual Emerging Growth Conference. The Oct. 23, 2025, report highlights the company’s lead product, AVERSA Fentanyl, an abuse-deterrent transdermal patch that releases aversive agents if tampered with, reducing the […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Partners with Brand Institute to Develop Global Brand Identity for AVERSA FENTANYL
October 10, 2025
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced that its subsidiary 4P Therapeutics has signed an agreement with Brand Institute, Inc., a global leader in pharmaceutical brand name and identity development, to create the worldwide commercial brand name and visual identity for AVERSA FENTANYL, the company’s lead product utilizing its AVERSA(TM) abuse-deterrent […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Files Provisional Patent to Strengthen Protection of AVERSA(TM) Abuse-Deterrent Technology
October 9, 2025
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the filing of a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA(TM) abuse-deterrent transdermal technology. The filing covers improved aversive formulations and coating application methods designed to enhance abuse deterrence and increase resistance to tampering. If […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
October 8, 2025
Nutriband (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Wednesday, Oct. 8, 2025, at 3 p.m. ET. The presentation will include a fireside Q&A session with questions from the live virtual audience, and registered investors can also schedule one-on-one meetings with Melnik. Interested attendees […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at MicroCap Rodeo Conference
September 25, 2025
Nutriband (NASDAQ: NTRB) announced it will participate in the MicroCap Rodeo Conference in New York City on Sept. 25, 2025. Company Chairman Serguei Melnik will present at 10 a.m., discussing operational highlights, growth initiatives, and the strategic direction for its AVERSA platform technology. The presentation will be webcast live, with registration available for interested parties. […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Eyes Clear Development Pathway for AVERSA(TM) Technology
September 19, 2025
Nutriband (NASDAQ: NTRB) is a transdermal pharmaceutical developer that has secured crucial FDA engagement for its lead abuse-deterrent technology. “Nutriband’s FDA Type C Meeting approval for AVERSA(TM) Fentanyl signals agency recognition of the product’s potential to address critical unmet medical needs. The Sept. 18 meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl
September 10, 2025
Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted by revenue of $1.29 million, up 50.87% year over year, and cash reserves of $6.9 million. The company said the strong balance sheet supports the advancement of AVERSA(TM) Fentanyl, its lead product candidate, which has a Type C FDA meeting […]
Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation
September 10, 2025
The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially important. Market Confidence Meets Innovation Nutriband (NASDAQ: […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Scales Manufacturing, Eyes Global Commercialization of AVERSA(TM)
September 9, 2025
Nutriband (NASDAQ: NTRB) was featured in a recent publication that discussed the company’s milestones, innovative platform, and lead product, AVERSA(TM) Fentanyl. NTRB’s technology “incorporates aversive agents into fentanyl patches to prevent misuse and accidental exposure. The company has built a global IP protection strategy, securing patents across the United States, Europe, Asia and Australia. With […]
Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference
September 8, 2025
The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures $5.3 Million from Warrant Exercises to Advance AVERSA Fentanyl NDA
September 4, 2025
Nutriband (NASDAQ: NTRB), a company developing abuse deterrent pharmaceutical products, announced the exercise of warrants at a strike price of $6.43, generating $5,306,000 in proceeds. The funds will support the remaining clinical development of AVERSA Fentanyl and submission of its New Drug Application (NDA) with the U.S. Food and Drug Administration. AVERSA Fentanyl, which could […]
Nutriband Inc. (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity
August 20, 2025
The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic options, particularly in pain management where the balance between therapeutic benefit and abuse potential creates urgent medical need alongside substantial regulatory complexity. The […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
August 18, 2025
Nutriband (NASDAQ: NTRB) announced it will participate in the Emerging Growth Conference on August 20, 2025. Chairman Serguei Melnik will deliver a live, interactive presentation and may open the floor for real-time questions from shareholders and the investment community. To view the full article, visit https://ibn.fm/GH7H3 About Nutriband Inc. We are primarily engaged in the development […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Steps Aside Temporarily to Run for Irish Presidency
August 11, 2025
Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will step aside for three months to pursue candidacy in the Irish Presidential election, with nomination hearings and voting taking place in September and October. Co-Founder and Chairman Serguei Melnik, a corporate strategy expert with over 20 years in capital markets, will assume CEO duties during this […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures FDA Type C Meeting for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
August 8, 2025
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the U.S. Food and Drug Administration has granted a Type C Meeting on Sept. 18, 2025, to review Chemistry, Manufacturing, and Controls plans for its lead product, AVERSA(TM) Fentanyl. Developed in partnership with Kindeva, the patch integrates Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl […]
Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech
August 6, 2025
Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to deliver medications that require careful balancing of patient access with strong mitigation against misuse. Drug delivery plays a […]
Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone
August 5, 2025
Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug’s safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable risks reach patients. Recognizing the immense […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB): Innovation Meets Science Through Scalable Platform
July 25, 2025
Nutriband (NASDAQ: NTRB) is positioning at the forefront of abuse-deterrent drug delivery in advancing its flagship fentanyl patch and buprenorphine candidates. The company combines transdermal innovation with abuse-deterrent science to meet critical public health needs. According to Nurtiband, AVERSA Fentanyl, with the possibility to reach peak annual U.S. sales of $80 to $200 million, holds […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sets Key Dates for 25% Preferred Stock Dividend
July 18, 2025
Nutriband (NASDAQ: NTRB) is reminding shareholders of its upcoming 25% preferred stock dividend. Shareholders of record as of July 25, 2025, will receive one preferred share for every four common shares held, with the dividend payable on August 5. Each preferred share will be convertible to one common share upon FDA approval of Nutriband’s AVERSA […]
InvestorNewsBreaks – Rare Biotech Story: Nutriband Inc. (NASDAQ: NTRB) Founder Shares Vision in Smart Money Circle Podcast
July 11, 2025
Nutriband (NASDAQ: NTRB) was recently featured on the Smart Money Circle Show, where Serguei Melnik, NTRB’s founder and president, unveiled his no-nonsense approach to biotech entrepreneurship. Standing in stark contrast to the conventional playbook are his grounded tone and unwavering focus on long-term value. An article discussing this reads, “Unlike most early-stage biotech companies, Nutriband […]
Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis
July 3, 2025
The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe pain, their high abuse potential has led to a growing demand for smarter, safer delivery systems. As policymakers, healthcare providers, and regulators seek solutions that balance medical necessity […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Declares 25% Preferred Stock Dividend Linked to AVERSA Fentanyl Approval
July 2, 2025
Nutriband (NASDAQ: NTRB) announced that its Board of Directors has approved a 25% preferred stock dividend, granting one preferred share for every four common shares held as of July 25, 2025, with distribution set for August 5. Each preferred share will convert to one common share upon FDA approval of the Company’s AVERSA Fentanyl product. […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Added to Four Russell Indexes in 2025 Reconstitution
July 1, 2025
Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. CEO Gareth Sheridan called the inclusion a reflection of market recognition and momentum behind the company’s AVERSA pipeline, particularly AVERSA Fentanyl, which has potential peak annual U.S. […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Price Target Raised to $15 Following AVERSA Fentanyl Manufacturing Milestone
June 23, 2025
Nutriband (NASDAQ: NTRB) has received a new $15 price target in an updated report from Robert LeBoyer, Senior Vice President and Equity Research Analyst, Biotechnology, at Noble Capital Markets, following the successful completion of commercial manufacturing and scale-up for AVERSA Fentanyl, its abuse-deterrent transdermal patch developed in partnership with Kindeva. The report highlights this milestone […]
Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation
June 20, 2025
The opioid crisis remains one of the most persistent public health emergencies in the U.S. While state and federal initiatives have helped curb some of the worst-case trajectories, more than 100,000 Americans still die each year from drug overdoses, a significant proportion linked to synthetic opioids like fentanyl. The crisis is evolving, not disappearing, and […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Advances Aversa Fentanyl with Kindeva to Commercial Manufacturing Scale
June 18, 2025
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the successful commercial manufacturing process scale-up of its lead product, Aversa™ Fentanyl, in collaboration with Kindeva, a global CDMO specializing in drug-device combinations. Aversa Fentanyl integrates Nutriband’s AVERSA™ abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch and is produced at Kindeva’s U.S.-based transdermal facility. The […]
Nutriband Inc. (NASDAQ: NTRB) Reports Double-Digit Revenue Increase, Continued Progress on AVERSA Fentanyl Development
June 12, 2025
A wave of positive developments continues to build momentum for Nutriband (NASDAQ: NTRB), with recent capital funding, strategic partnerships and an expanded intellectual property portfolio reinforcing its bid to lead in the development of safer transdermal therapies. Nutriband is positioning itself at the forefront of abuse-deterrent drug delivery by advancing its Aversa platforms, notably its […]